Characteristics of patients achieving stable disease
| Age . | Sex . | Cancer diagnosis . | No. of prior therapies . | 5-AZA cohort/dose (mg/m2) . | SD duration (mo) . | Decrease in methylation (%) . | Histone acetylation . |
|---|---|---|---|---|---|---|---|
| 72 | M | Renal cell | 6 | 20 | 6 | n/a | Yes |
| 44 | F | Ethmoidal | 1 | 20 | 4 | 7 | No |
| 72 | F | LMS of uterus | 3 | 25 | 8 | 9 | Yes |
| 61 | F | Thymic carcinoid | 3 | 25 | 4 | 6 | No |
| 41 | F | Breast | 6 | 25 | 4 | 6 | No |
| 50 | F | Ocular melanoma | 1 | 47 | 6 | 4 | Yes |
| 64 | M | Colorectal | 1 | 47 | 4 | 3 | n/a |
| 58 | M | Papillary thyroid | 2 | 59 | 12 | 5 | Yes |
| 49 | M | Thymoma | 1 | 59 | 4 | 17 | Yes |
| 62 | F | Melanoma | 9 | 75 | 10 | 16 | Yes |
| 43 | F | Thymoma | 3 | 94 | 6 | 13 | n/a |
| 36 | F | Ocular melanoma | 0 | 94 | 4 | 9 | Yes |
| 60 | M | Prostate | 4 | 75 | 6 | n/a | n/a |
| 61 | F | Salivary | 2 | 75 | 6 | n/a | n/a |
| Age . | Sex . | Cancer diagnosis . | No. of prior therapies . | 5-AZA cohort/dose (mg/m2) . | SD duration (mo) . | Decrease in methylation (%) . | Histone acetylation . |
|---|---|---|---|---|---|---|---|
| 72 | M | Renal cell | 6 | 20 | 6 | n/a | Yes |
| 44 | F | Ethmoidal | 1 | 20 | 4 | 7 | No |
| 72 | F | LMS of uterus | 3 | 25 | 8 | 9 | Yes |
| 61 | F | Thymic carcinoid | 3 | 25 | 4 | 6 | No |
| 41 | F | Breast | 6 | 25 | 4 | 6 | No |
| 50 | F | Ocular melanoma | 1 | 47 | 6 | 4 | Yes |
| 64 | M | Colorectal | 1 | 47 | 4 | 3 | n/a |
| 58 | M | Papillary thyroid | 2 | 59 | 12 | 5 | Yes |
| 49 | M | Thymoma | 1 | 59 | 4 | 17 | Yes |
| 62 | F | Melanoma | 9 | 75 | 10 | 16 | Yes |
| 43 | F | Thymoma | 3 | 94 | 6 | 13 | n/a |
| 36 | F | Ocular melanoma | 0 | 94 | 4 | 9 | Yes |
| 60 | M | Prostate | 4 | 75 | 6 | n/a | n/a |
| 61 | F | Salivary | 2 | 75 | 6 | n/a | n/a |
Abbreviations: SD, stable disease; n/a, not available; LMS, leiomyosarcoma.